These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 35406568)

  • 1. Genetic and Epigenetic Characterization of Sarcoma Stem Cells Across Subtypes Identifies EZH2 as a Therapeutic Target.
    O'Donnell E; Muñoz M; Davis R; Randall RL; Tepper C; Carr-Ascher J
    bioRxiv; 2024 May; ():. PubMed ID: 38798385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erratum to: PGRMC1 contributes to doxorubicin-induced chemoresistance in MES-SA uterine sarcoma.
    Lin ST; May EW; Chang JF; Hu RY; Wang LH; Chan HL
    Cell Mol Life Sci; 2015 Jun; 72(12):2411-3. PubMed ID: 25687505
    [No Abstract]   [Full Text] [Related]  

  • 3. Similar additive effects of doxorubicin in combination with photon or proton irradiation in soft tissue sarcoma models.
    Bernardo T; Behrends C; Klein D; Kuntze A; Timmermann B; von Neubeck C
    Front Oncol; 2023; 13():1211984. PubMed ID: 37503316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers.
    Ishihara Y; Nakamura K; Nakagawa S; Okamoto Y; Yamamoto M; Furukawa T; Kawahara K
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating soft tissue sarcomas with adjuvant chemotherapy.
    Patrikidou A; Domont J; Cioffi A; Le Cesne A
    Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histology-driven chemotherapy in soft tissue sarcomas.
    Scurr M
    Curr Treat Options Oncol; 2011 Mar; 12(1):32-45. PubMed ID: 21359911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soft Tissue Sarcoma Study: Association of Genetic Alterations in the Apoptosis Pathways with Chemoresistance to Doxorubicin.
    Kirilin EM; Fetisov TI; Moiseeva NI; Lesovaya EA; Laletina LA; Makhmudova LF; Manikaylo AE; Fomina LY; Burov DA; Bokhyan BY; Zinovieva VY; Vilkova AS; Mekheda LV; Kozlov NA; Scherbakov AM; Belitsky GA; Švedas V; Kirsanov KI; Yakubovskaya MG
    Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perspectives of Cell Sensitivity/Resistance Assay in Soft Tissue Sarcomas Chemotherapy.
    Fetisov TI; Khazanova SA; Shtompel PA; Trapeznikova ES; Zinovieva VY; Marshall VI; Lovenger AA; Rogozhin DV; Anastasia TA; Bokhyan BY; Belitsky GA; Yakubovskaya MG; Kirsanov KI
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Multiple Drug Resistance Mechanism in Different Types of Soft Tissue Sarcomas: Assessment of the Expression of ABC-Transporters, MVP, YB-1, and Analysis of Their Correlation with Chemosensitivity of Cancer Cells.
    Moiseeva NI; Laletina LA; Fetisov TI; Makhmudova LF; Manikaylo AE; Fomina LY; Burov DA; Lesovaya EA; Bokhyan BY; Zinovieva VY; Vilkova AS; Mekheda LV; Kozlov NA; Scherbakov AM; Kirilin EM; Belitsky GA; Yakubovskaya MG; Kirsanov KI
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of Ifosfamide-doxorubicin chemotherapy in histology-specific, high grade, locally advanced soft tissue sarcoma, a 14-year experience.
    Goy BW; Syed S; Padmanabhan A; Burchette RJ; Helmstedter CS
    Radiother Oncol; 2021 Dec; 165():174-178. PubMed ID: 34758339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
    Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
    Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.